Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26893882 | 0.87 | GRM1 (0.45) | GRM5GRM1 | |
| SCHEMBL30003484 | 0.87 | GRM1 (0.45) | GRM5GRM1 | |
| SCHEMBL26697728 | 0.80 | QDPR (0.34) | ALDH1A1TDP1KMT2A | |
| SCHEMBL29025852 | 0.79 | QDPR (0.41) | ALDH1A1HPGDTDP1TSHRKMT2A | |
| SCHEMBL29025848 | 0.79 | QDPR (0.41) | ALDH1A1HPGDTDP1TSHRKMT2A | |
| SCHEMBL28559578 | 0.72 | TSHR (0.31) | ALDH1A1TSHRMAPK1KMT2A | |
| SCHEMBL29149637 | 0.71 | GAA (0.33) | ALDH1A1HPGDTDP1 | |
| SCHEMBL26894701 | 0.69 | GRM1 (0.42) | GRM5GRM1 | |
| SCHEMBL22119654 | 0.69 | QDPR (0.38) | ALDH1A1TDP1PRMT5GRM5GRM1 | |
| SCHEMBL12489502 | 0.68 | CHRM1 (0.52) | ALDH1A1GRM5SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022221227-A9 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. (US) | 2023-11-30 | — | — | WO | disclosed |